Submissions from 2023
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations, J. Thaddeus Beck, Meredith McKean, Shirish M. Gadgeel, Daniel W. Bowles, Rizwan Haq, Rona Yaeger, Matthew H. Taylor, Arnab K. Maity, Stefanie Drescher, Colleen Oliver, Ann M. Huelskamp, Gang Feng, and Keren Sturtz
Single-cell epigenomic analysis reveals an important role of the receptor kinase Ror2 in the erosion of cellular identity during pancreatic carcinogenesis, Simone Benitz, Malak Nasser, Alexander Steep, Ian Loveless, Hui-Ju Wen, Daniel Long, Erick T. Davis, Donald Rempinski, Michaela Louw, Jacee Moore, Nina Steele, Ujjwal Mahajan, Ivonne Regel, Filip Bednar, and Howard Crawford
First Report of Asymptomatic Solitary High-Grade B-Cell Lymphoma NOS: An Enigmatic Entity, Seif Bugazia, Nakul Gandhi, Niluka Weerakoon, and Geetika Kukreja
Efficacy of the Addition of RGI-2001 to Tacrolimus and Methotrexate for Acute Gvhd Prevention in Myeloablative HSCT Using HLA-Matched Donors, Yi-Bin Chen, Shatha Farhan, Lazaros J. Lekakis, Gary J. Schiller, Jean Adel Yared, Amer Assal, Dana D. Lee, Hayley Lane, Ted A. Gooley, Zachariah DeFilipp, and Ayman Saad
EFFICACY and SAFETY of the ADDITION of RGI-2001 IV INFUSION to TACROLIMUS and METHOTREXATE for ACUTE GVHD PREVENTION in MYELOABLATIVE HSCT, Yi Bin Chen, Shatha Farhan, Lazaros Lekakis, Gary Schiller, Jean Yared, Amer Assal, Dana Lee, Hayley Lane, Ted Gooley, Zachariah DeFilipp, and Ayman Saad
Incidence of Positive Sentinel Lymph Node in cN0(f) Breast Cancer Patients After Neoadjuvant Chemotherapy: Opportunity to Defer Intraoperative Frozen Section Analysis, Fallon Dimaano, Theresa Schwartz, Laura L. Susick, Elizabeth King MD, Christine Joliat, Anna Lehrberg, Lindsay Petersen, and Jessica Bensenhaver
EP10.01-03 A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC, A. Drilon, M. M. Awad, D. R. Camidge, P. M. Forde, M. Alexander, Shirish M. Gadgeel, L. C. Villaruz, J. Perez, T. Navas, C. Daly, S. Patel, S. Li, M. Laughlin, I. Lowy, H. Magnan, and P. Rietschel
Expression of Irf3 and Irf7 in tumour cells drives pancreatic cancer development and progression, Lisa Fahr, Simone Benitz, Tobias Straub, Jurik Mutter, Hannah Lisiecki, Ujjwal M. Mahajan, Georg Beyer, Katja Steiger, Andrea Terrasi, Gunnar Schotta, Axel Imhof, Kirsten Lauber, Jörg Kleeff, Christoph W. Michalski, Julia Mayerle, and Ivonne Regel
A Single Institution Randomized Clinical Trial Evaluating Ciprofloxacin Versus Levofloxacin As Antibacterial Prophylaxis for Patients Receiving Hematopoietic Stem Cell Transplantation, Shatha Farhan, Peter Xie, Klodiana Neme, Angela German, Nancy Mikulandric, Josena K. Stephen, Mary A. Trapp, Elizabeth A. Henne, Sarah Szymanski, Scott R. Rohrer, Danielle L. Pelland, Nada Zagar, Izabela Z. Mazur, Nada Rida, Kunj Patel, Min Wu, Neda Kortam, Aseel Yaseen, Aroob Sweidan, Josephine Emole, Edward Peres, Muneer H. Abidi, and Mayur Ramesh
MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC, Shirish M. Gadgeel, P. A. Jänne, A. I. Spira, S.-H. I. Ou, R. S. Heist, J. M. Pacheco, M. L. Johnson, J. K. Sabari, K. Leventakos, J. A. Mason, K. Velastegui, X. Yan, R. Chao, and G. J. Riely
1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A, Shirish M. Gadgeel, T. S. K Mok, S. Peters, E. Nadal, J-Y Han, J. A. Alatorre Alexander, N. Leighl, V. Sriuranpong, M. Pérol, G. D. Castro, F. de Marinis, D. S. W Tan, S. Paul, Z. J. Assaf, M. MacLennan, T. O. Lohmann, M. Slade, M. S. Mathisen, V. Bhagawati-Prasad, and R. Dziadziuszko
OA14.05 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%, Shirish M. Gadgeel, D. Rodríguez-Abreu, B. Halmos, M. C. Garassino, T. Kurata, Y. Cheng, E. Jensen, M. Shamoun, K. Rajagopalan, and L. Paz-Ares
EP12.01-64 Metastatic Non-Small Cell Lung Cancer With EGFR Mutations: Treatment Pattern and Outcomes From a Systematic Literature Review, Shirish M. Gadgeel, E. Wang, S. Phani, C. Wu, M. Salas, J. Meng, F. Diamand, S. Esker, and D. W-T Lim
1388P Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC), Shirish M. Gadgeel, Q. Zhang, H. Lin, O. Fajardo, H. Trinh, S. Arndorfer, S. Kong, A. Rahman, S. Li, V. R. Archer, and J. F. Gainor
Characteristics and outcomes of patients with small cell lung cancer (SCLC) detected with CT screening at a single health system, Manasi M. Godbole, Pin Li, Kashmira Wani, Matthew Meranda, Michael J. Simoff, and Shirish M. Gadgeel
Lowering the bar for consideration of neoadjuvant chemotherapy in early-stage HER2- positive breast cancers, Manasi M. Godbole, Matthew Meranda, Kathren Shango, and Vrushali S. Dabak
P2.09-39 Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers, Radhika Gutta, Fawzi Abu Rous, E. Teslow, E. Jaeger, Shirish M. Gadgeel, and Bindu Potugari
43001 Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis, Omid Hamid, Amy Weise, Karl D. Lewis, Tae M. Kim, Meredith McKean, Nehal J. Lakhani, John Kaczmar, Kyriakos P. Papapoulos, Shuquan Chen, Jayakumar Mani, and Giuseppe Gullo
TIP XMT-1660: A Phase 1b Trial of a B7-H4 Targeted Antibody- Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers, Erika Hamilton, Alexander Spira, Sylvia Adams, Nour Abuhadra, Antonio Giordano, Ritesh Parajuli, Hyo Han, Amy Weise, Aubri Marchesani, Kate Josephs, Arvind Chaudhry, and Kevin Kalinsky
XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers, Erika Hamilton, Alexander Spira, Sylvia Adams, Nour Abuhadra, Antonio Giordano, Ritesh Parajuli, Hyo Han, Amy Weise, Aubri Marchesani, Kate Josephs, Arvind Chaudhry, and Kevin Kalinsky
XMT-1660: A Phase 1b trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers (1250), Erika Hamilton, Alexander Spira, Sylvia Adams, Nour Abuhadra, Antonio Giordano, Ritesh Parajuli, Hyo Han, Amy Weise, Aubri Marchesani, Kate Josephs, Arvind Chaudhry, and Kevin Kalinsky
Efficacy and Safety of Eptacog Beta (Recombinant Activated FVII) in Patients with Hemophilia A or B with Inhibitors According to Time to Initial Infusion: A Post-Hoc Analysis from PERSEPT-1, C. Hermans, M. Escobar, Y. Abajas, S. Acharya, M. Alvarez-Román, G. Batsuli, Y. Dargaud, M. Janbain, Philip Kuriakose, J. Mahlangu, M. Mancuso, W. Miesbach, S. Yuan, I. Mitchell, and M. Carcao
Post-Transfusion Purpura: A Literature Review, Oscar Hinojosa, Omar Ammari, Linda Albusoul, Philip Kuriakose, and Zaher K. Otrock
Infusion Reactions with Alternative Therapies during the National Shortage of Iron Dextran, Brigid Jacob, Maria Jamil, Shahm Raslan, Zeinab Nasser, Kylie Springer, Angela Michael German, and Philip Kuriakose
Efficacy of Direct Oral Anticoagulants Vs Warfarin Vs Low Molecular Weight Heparin in the Treatment of Acute Splanchnic Vein Thrombosis in Patients with Underlying Myeloproliferative Disorder, Maria Jamil, Zeinab Nasser, Brigid Jacob, Ruchi Mangal, and Vijaya Donthireddy
8MO Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency, P. A. Jänne, A. Spira, G. J. Riely, Shirish M. Gadgeel, R. Heist, S. H. I. Ou, M. L. Johnson, J. Sabari, K. Velastegui, J. G. Christensen, W. Yang, K. Anderes, R. Chao, and C. Paweletz
81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study, M. L. Johnson, S. H. I. Ou, E. Felip, C. Baik, B. Besse, J. Mazieres, D. R. Camidge, Shirish M. Gadgeel, A. Drilon, Y. Y. Elamin, G. Liu, J. E. Reuss, T. Kehrig, H. E. Pelish, V. Zhu, and J. J. Lin
A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma, Mandana Kamgar, Husain Y. Khan, Amro Aboukameel, Sahar Bannoura, Brian Y. Chung, Aniko Szabo, Yiwei Li, Mohammed N. Al Hallak, Philip A. Philip, Ben George, Kathleen K. Christians, Douglas B. Evans, Susan Tsai, Beth Erickson, Sanjeev Luther, Asfar S. Azmi, and William A. Hall
Epidemiology and Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A US Population-Based Study, Ujjwal Karki, Pravash Budhathoki, Anish Shah, Bipin Ghimire, Shyam K. Poudel, and Mohammad Muhsin Muhsin Chisti
Real World Analysis of G6PD Testing Prior to the Use of Rasburicase in Hematologic Malignancies; A Single Center Experience, Radhika Kulkarni, Oscar Hinojosa, and Vijayalakshmi Donthireddy
A perilous and complicated situation in hospitals: Vitamin D deficiency in multiple myeloma patients-A nationwide cross-sectional study, Manisha R. Lakhanpal, Nikhila Chelikam, Divesh Manjani, Simmy Lahori, Sai A. Akella, Prashanth G. Shivashankar, Shlok V. Shah, Abdirazak Ali, Varneet Toor, Aryak Singh, Rahul Gujarathi, Lokesh Manjani, Urvish Patel, Avinash Adiga, and Geetika Kukreja
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers), Michael S. Lee, Aparna R. Parikh, David R. Spigel, Farshid Dayyani, Alexander I. Spira, Chloe E. Atreya, Susanna V. Ulahannan, John H. Strickler, Marwan Fakih, Patrick Grierson, Eric Christenson, Darryl Outlaw, Gazala Khan, Scott Kopetz, Andrea J. Bullock, Zhengrong Li, Xiaoying Chen, Hina Patel, Saswati Hazra, and E. Gabriela Chiorean
NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US), Christopher H. Lieu, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim H. Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Arvind Dasari
Phase 1 Trial of Kt-413, a Degrader of Irak4 and Imid Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphomas, J. K. Lue, D. A. Stevens, E. Ayers, K. Dunleavy, Ahmad Mattour, A. Mishkin, A. McDonald, S. Agarwal, P. Henrick, R. Perea, A. Gollerkeri, J. Gollob, and J. Westin
Creation and evaluation of oral anticancer agent (OAA) management resources for a thematic quality improvement program, Emily R. Mackler, Victoria Nachar, Marjorie A. Curry, Diana Kostoff, Angela Wood, Stephanie Mayfield, Brooke Boring, and Karen B. Farris
Multisite results from a practice-based self-assessment for oral anticancer agent (OAA) management, Emily R. Mackler, Victoria Nachar, Marjorie A. Curry, Diana Kostoff, Angela Wood, Stephanie Mayfield, Brooke Boring, and Karen B. Farris
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis, Inderjit Mehmi, Karl D. Lewis, Amy M. Weise, Meredith McKean, Kyriakos P. Papadopoulos, John Crown, Sajeve S. Thomas, Eugenia Girda, John M. Kaczmar, Kevin B. Kim, Nehal J. Lakhani, Melinda L. Yushak, Omid Hamid, Jayakumar Mani, Fang Fang, Israel Lowy, and Giuseppe Gullo
EFFICACY AND SAFETY OF EPTACOG BETA (RECOMBINANT HUMAN FVIIA) ACCORDING TO AGE IN PERSONS WITH HAEMOPHILIA A/B WITH INHIBITORS UNDERGOING SURGICAL PROCEDURES, W. Miesbach, M. Escobar, L. Boggio, S. Bonanad, G. Castaman, Y. Darguard, A. Giermasz, C. Hermans, Philip Kuriakose, D. Quon, M. Reding, D. Q. Tran, J. Windyga, D. Bonzo, C. Macie, and J. Mahlangu
LUMINOS-102: Lerapolturev with and without α-PD- 1 in unresectable α-PD- 1 refractory melanoma, Justin Moser, Ding Wang, C. L. Cowey, Evan Pisick, Douglas B. Johnson, Joanna Kolodney, Meghan J. Mooradian, Andrew L. Pecora, Andrew S. Poklepovic, Alan Tan, Sajeve S. Thomas, Daniel Corum, Shannon R. Morris, Hannah Kittinger, Jessica Sorrentino, William G. Nichols, and Yana G. Najjar
Closing the Gap on Racial Disparities in Pancreas Cancer -the Impact of a Multidisciplinary Clinic for Surgical Patients with Pancreatic Adenocarcinoma (PDAC) in an Integrated, Tertiary Healthcare System, Georges Nassif, Meng-Hua Tao, Kendyll J. Gartrelle, Julie Clark, Kyra Langley, Farzan Siddiqui, Parag J. Parikh, Gazala Khan, Philip A. Philip, Rupen Shah, Christopher Steffes, and David Kwon
Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT), Nitin Ohri, Shruti Jolly, Benjamin T. Cooper, Rafi Kabarriti, William R. Bodner, Jonathan Klein, Chandan Guha, Shankar Viswanathan, Elaine Shum, Joshua K. Sabari, Haiying Cheng, Rasim A. Gucalp, Enrico Castellucci, Angel Qin, Shirish M. Gadgeel, and Balazs Halmos
Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922, Michael J. Overman, Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Sarah Colby, Marwan Fakih, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies, Krish Patel, Sarah Rothman, Poulomee A. Das, Stephanie Yee, Indu Ramachandran, Iphigenia Koumenis, Terry A. Cook, Ying Yuan, Nikolaus S. Trede, and Ahmad H. Mattour
Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study, M. R. Patel, T. Doi, T. Koyama, G. S. Falchook, C. F. Friedman, S. A. Piha-Paul, M. Gutierrez, M. M. Awad, Abdelwahab H. Mattour, T. Satoh, N. Okamoto, J. Singh, N. Yoshizuka, M. Qian, X. .. Qian, B. P. Tran, O. Dosunmu, P. Lu, and M. L. Johnson
Factors Associated with in-Hospital Mortality in Patients with Burkitt Lymphoma - Analysis of the National Inpatient Sample (NIS), Rayli Pichardo, Aula Ramo, Yazan Abu Omar, and Vrushali S. Dabak
Prognostic Factors in Hospitalized Patients with HIV-Associated Burkitt's Lymphoma - Real World Data Analysis, Rayli Pichardo, Aula Ramo, Yazan Abu Omar, and Vrushali S. Dabak
A phase I study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors, H. Prenen, T. Lesimple, M. Robert, J-P. Machiels, B. R. Delafontaine, P. Tomasini, T. Meniawy, N. Kotecki, E. Van Cutsem, S. A. Piha-Paul, M. T. Schweizer, Shirish Gadgeel, S. Kondo, K. Ouali, Y. Kuboki, J. Daniel, V. Ebiana, J. Howe, S. Spitz, and A. Italiano
P2.06-08 Phase I/II Study of Rucaparib and Pembrolizumab Maintenance in Stage IV NSCLC after Carboplatin, Pemetrexed, Pembrolizumab, A. Qin, D. Morgensztern, S. Waqar, D. Owen, Shirish M. Gadgeel, B. Schneider, G. Kalemkerian, J. Rice, and N. Ramnath
A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613, Kanwal P. S Raghav, Katherine A. Guthrie, Scott Kopetz, Benjamin R. Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman, Arvind Dasari, Larry R. Corum, Lee G. Hicks, Mital Patel, Benjamin T. Esparaz, Syed Mohammad A. Kazmi, Nitya Alluri, Sarah Colby, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
ATHN 11: Observational Study of Long-Term Outcomes of Liver Transplantation, Margaret V. Ragni, Jessica Callis, Nabil Daoud, Brian Hu, Matthew Manuel, Jarren Santos, Jonathan Schwartz, Kenneth D. Friedman, Peter Kouides, Philip Kuriakose, Andrew D. Leavitt, Ming Y. Lim, Nicoletta Machin, Michael Recht, and Tammuella Chrisentery-Singleton
APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation-ECOG-ACRIN EA2192, Kim A. Reiss, Sung C. Hong, Anup Kasi, Eileen M. O'Reilly, Shishir K. Maithel, Xin Yao, Stanley R. Hamilton, Ben Boursi, Michael J. Pishvaian, Samuel J. Klempner, Susan M. Domchek, Paul J. Catalano, E. Gabriel Chiorean, Philip A. Philip, and Peter J. O'Dwyer
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non-small cell lung cancer (NSCLC), Joshua E. Reuss, Sunil G. Gandhi, David R. Spigel, Pasi A. Janne, Luis G. Paz-Ares, Shirish M. Gadgeel, Jyoti D. Patel, Francesco Passiglia, Alexander I. Spira, Martin J. Edelman, George R. Blumenschein, Ardaman Shergill, Timothy F. Burns, Vijeta Bhambhani, Gloria Patrick, Jonathan A. Pachter, Louis J. Denis, and D. Ross Camidge
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study, Dan-yun Ruan, Myung A. Lee, Yanhong Deng, Keun-Wook Lee, Michael Millward, Jaspreet S. Grewal, Shirish M. Gadgeel, Rachel E. Sanborn, Xinfang Hou, Shaozhong Wei, Seok J. Huh, Fu-Rong Liu, Xiaoxi Xie, Ziyong Xiang, Zhe Shi, Yaolin Wang, Ling Zhang, Gary E. Richardson, and Rui-Hua Xu
Expression of lysine demethylase 5a (Kdm5a) influences tumour aggressiveness in murine pancreatic cancer cells, Nicole Schreiner, Lisa Fahr, Simone Benitz, Quan Zhou, Ahmed Alnatsha, Axel Imhof, Ujjwal Mahajan, Julia Mayerle, and Ivonne Regel
Comprehensive review of patients with hematologic malignancies in a cancer urgent care center: A single center experience, Muhammad A. Shahid, Linda Albusoul, Sruthi Ramanan, Radhika Gutta, Kylie Springer, Courtney M. Rose, and Philip Kuriakose
Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors, Aditi Shastri, Eric J. Feldman, Alexander N. Starodub, Tatyana Feldman, Cristina P. Rodriguez, Zachary D. Epstein-Peterson, Don A. Stevens, Adam J. Olszewski, Auris O. Huen, Pierluigi Porcu, John C. Reneau, Stefan K. Barta, Enrica Marchi, Ahmad H. Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Sean Donohue, Joyoti Dey, Sagar Agarwal, Rahul Karnik, Ashwin Gollerkeri, Jared Gollob, and Stephen D. Smith
SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers, Rachna T. Shroff, Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin, Amit Mahipal, Aparna Kalyan, Milind M. Javle, Carol Aghajanian, Benjamin R. Tan, Puneet S. Cheema, Anuj K. Patel, Renuka V. Iyer, Robin K. Kelley, Jaykumar R. Thumar, Anthony B. El-Khoueiry, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
OA10.03 Assessing Availability and Demand for Patient-Friendly Resources in Lung Cancer Care: The Patient Perspective, E. K. Singh, A. Desai, Fawzi Abu Rous, and J. Feldman
Preliminary Analysis of ATHN 16: Real-World Safety of Eptacog Beta, T. Singleton, S. Acharya, S. Ahuja, L. Amos, D. Bonzo, A. Eason, M. Escobar, C. Knoll, Philip Kuriakose, E. Lagrue, M. Recht, S. Sullivan, D. Quon, and M. Reding
False positive PET scan in patients with treated malignancy following COVID-19 vaccination, Alexander A. Slota, Vrajesh Parmar, Amy M. Weise, and Ding Wang
Trials in progress: Alliance A022104/NRG-GI010-A randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer (LARC; the Janus Rectal Cancer trial), Jesse J. Smith, Arvind Dasari, Qian Shi, Julio Garcia-Aguilar, Hanna K. Sanoff, Thomas J. George, Theodore S. Hong, Greg Yothers, Philip A. Philip, Garth D. Nelson, Tareq Al Baghdadi, Olatunji B. Alese, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Ardaman Shergill, Natally Horvat, Paul B. Romesser, and William A. Hall
Phase 1 Trial of Kt-333, a Stat3 Degrader, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia and Solid Tumors, S. Smith, A. Olszewski, A. N. Starodub, D. A. Stevens, T. Feldman, P. Porcu, Z. Epstein-Peterson, A. Huen, L. Pinter-Brown, Ahmad Mattour, R. Perea, A. Gollerkeri, J. Dey, C. Klaus, S. Agarwal, J. Gollob, and A. Shastri
2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC), S. Sridhar, P. H. O'Donnell, T. W. Flaig, J. E. Rosenberg, C. J. Hoimes, M. I. Milowsky, S. Srinivas, S. George, R. R. McKay, D. P. Petrylak, P. M. Coelho Barata, Clara Hwang, M. Cruz-Correa, M. Iafolla, M. Mckean, R. Dreicer, S. Brancato, J. J. Lukas, Y. Yu, and H. Moon
Polygenic risk scores in assessing lung cancer susceptibility in non-Hispanic White and Black populations, Matthew R. Trendowski, Chrissy Lusk, Angie Wenzlaff, Christine Neslund-Dudas, Shirish M. Gadgeel, Ayman Soubani, and Ann G. Schwartz
Preliminary results from ERAS-007 plus palbociclib (palbo) in patients (pts) with KRAS/ NRAS mutant (m) colorectal cancer (CRC) or KRASm pancreatic ductal adenocarcinoma (PDAC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogenactivated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers), Susanna V. Ulahannan, David R. Spigel, Michael S. Lee, Marwan Fakih, Patrick Grierson, Eric Christenson, E. Gabriela Chiorean, Darryl A. Outlaw, Gazala Khan, Chloe E. Atreya, Aparna R. Parikh, Farshid Dayyani, Alexander I. Spira, Scott Kopetz, Andrea J. Bullock, Zhengrong Li, Xiaoying Chen, Hina Patel, Saswati Hazra, and John H. Strickler
Does Implementing Calendars Outlining Inpatient Chemotherapy Schedules in Patient Rooms Improve Patient's Experience?, Kashmira Wani and Vrushali S. Dabak
Comparison of Maintenance Therapy Regimens of Patients Treated for Multiple Myeloma, Kashmira Wani, Radhika Gutta, Aayush Mittal, Maria Jamil, Kylie Springer, and Philip Kuriakose
Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma, Kashmira Wani, Radhika Gutta, Aayush Mittal, Maria Jamil, Kylie Springer, and Philip Kuriakose
A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC), Leah Wells, Angel Qin, John Rice, Shirish M. Gadgeel, Bryan J. Schneider, Nithya Ramnath, Lili Zhao, and Gregory P. Kalemkerian
Modeling Risk of Atrial Fibrillation in Stem Cell Transplant, Min Wu, Rayli Pichardo, Sowjanya Vuyyala, Josephine Emole, Edward Peres, Muneer H. Abidi, Madhulata Reddy, and Shatha Farhan
Submissions from 2022
Racial and gender disparities in next-generation sequencing for pancreatic adenocarcinoma, Fawzi Abu Rous, Sunny R. K Singh, Chun-Hui Lin, Laila M. Poisson, and Gazala Khan
(P44) Is Prophylactic Cranial Irradiation Necessary in Stage I-IIA Small Cell Lung Cancer Patients? A Single Institution Experience, Sondos Alkhatib, Aharon Feldman, Shirish M. Gadgeel, Andrew Popoff, Munther Ajlouni, Michael Simoff, and Benjamin Movsas
1544P Pre-treatment CT radiomics predicts survival in chemo-immunotherapy-treated small cell lung cancer, Joseph Bae, Prateek Prasanna, and Shirish M. Gadgeel
An Unsupervised Autoencoder Developed from Dynamic Contrast-Enhanced (DCE)-MRI Datasets for Classification of Acute Tumor Response in an Animal Model, Hassan Bagher-Ebadian, Tavarekere N. Nagaraja, Glauber Cabral, Katelynn G. Farmer, Olivia Valadie, P. Acharya, Benjamin Movsas, Stephen L. Brown, Indrin J. Chetty, and James R. Ewing
Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer, Z. Bakouny, P. Grover, C. Labaki, J. Awosika, S. Gulati, C. Y. Hsu, M. A. Bilen, O. Eton, L. Fecher, Clara Hwang, H. Khan, R. R. McKay, E. Ruiz, L. Weissmann, M. A. Thompson, D. Shah, J. Warner, Y. Shyr, T. K. Choueiri, and T. Wise-Draper
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS mutation, Tanios S. Bekaii-Saab, Alexander I. Spira, Rona Yaeger, Gary L. Buchschacher, Autumn Jackson McRee, Joshua K. Sabari, Melissa L. Johnson, Minal A. Barve, Navid Hafez, Karen Velastegui, James G. Christensen, Thian Kheoh, Hirak Der-Torossian, and Igor I. Rybkin
Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study, B. Besse, M. Johnson, S. H. I. Ou, Shirish M. Gadgeel, A. Spira, J. Lin, E. Felip, A. J. van der Wekken, A. Calles, M. J. de Miguel, D. R. Camidge, Y. Elamin, G. D. L. Lopes, S. Liu, J. Bauman, D. Haggstrom, G. Riley, H. E. Pelish, V. W. Zhu, and A. Drilon
A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC), Mark E. Burkard, Meredith McKean, Jordi R. Ahnert, Niharika B. Mettu, Jeremy C. Jones, Jamal G. Misleh, Wen W. Ma, Kian-Huat Lim, E. Gabriela Chiorean, Michael J. Pishvaian, Shirish M. Gadgeel, Heidi A. McKean, Brent Kreider, Deb Knoerzer, Anna Groover, Mary L. Varterasian, Jessica A. Box, Caroline Emery, and Ryan J. Sullivan
Utility of interval imaging during neoadjuvant treatment of locoregional breast cancer, Rebecca Chacko, Pin Li, Nayef H. Abdel-Razeq, Manasi Godbole, and Vrushali S. Dabak
DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study, T. Doi, M. Patel, G. S. Falchook, T. Koyama, C. F. Friedman, S. Piha-Paul, M. E. Gutierrez, Raghan Abdul-Karim, M. Awad, D. R. Adkins, S. Takahashi, S. Kadowaki, B. Cheng, N. Ikeda, A. Laadem, N. Yoshizuka, M. Qian, O. Dosunmu, H-T. Arkenau, and M. L. Johnson
Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors, A. Drilon, B. Besse, D. R. Camidge, S. H. I Ou, Shirish M. Gadgeel, M. L. Johnson, A. Calles, M. J. de Miguel, A. I. Spira, E. Felip, G. Lopes, A. J. van der Wekken, Y. Y. Elamin, J. Green, Y. Sun, J. Soglia, V. W. Zhu, and J. J. Lin
A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC, Alexander E. Drilon, Mark M. Awad, Shirish M. Gadgeel, Liza C. Villaruz, Joshua K. Sabari, Javier Perez, Christopher Daly, Shraddha Patel, Siyu Li, Frank A. Seebach, Israel Lowy, Heather D. Magnan, and Petra Rietschel
EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study, A. Drilon, S. H.I Ou, Shirish M. Gadgeel, M. Johnson, A. Spira, G. Lopes, B. Besse, E. Felip, A. J. van der Wekken, A. Calles, M. J. de Miguel, D. R. Camidge, Y. Elamin, S. Liu, J. Bauman, D. Haggstrom, G. Riley, H. E. Pelish, V. W. Zhu, and J. J. Lin
Does contralateral prophylactic mastectomy improve survival in triple negative breast cancer?, Genevieve A. Fasano, Solange Bayard, Yalei Chen, Jennifer Marti, Rache Simmons, Alexander Swistel, Jessica Bensenhaver, S. David Nathanson, Lindsay Petersen, Erica Proctor, Melissa Davis, and Lisa Newman
Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers, Siqing Fu, Lisle Nabell, Alexander T. Pearson, Rom Leidner, Douglas Adkins, Marshall R. Posner, Jorge J. Nieva, Debra L. Richardson, Agustin Pimentel, Sanjay Goel, Stuart J. Wong, Alan L. Ho, Ari Rosenberg, Matthew H. Taylor, Raghad Abdul-Karim, Corinne Iacobucci, Xiaoping Qing, Kia Katchar, Katia Schlienger, and David G. Pfister
1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC), Shirish M. Gadgeel, J. Al-Mondhiry, M. J. Ahn, S. W. Kim, L. Paz-Ares, H. Prenen, M. Boyer, J. G. Bustamanta Alvarez, B. Solomon, S. Huang, M. Minocha, M. Kistler, and N. Hashemi Sadraei
Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD), Shirish M. Gadgeel, J. Gainor, F. Cappuzzo, E. Garralda, D. H. Lee, J. Mazieres, D. W. Kim, V. Zhu, G. Lopes, S. Miller, M. Nowicka, H. Trinh, S. M. Arndorfer, A. Rahman, J. Noe, Q. Zhang, and V. Subbiah
973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC, M. C. Garassino, Shirish M. Gadgeel, G. Speranza, E. Felip, E. Esteban Gonzalez, M. Domine Gomez, M. J. Hochmair, S. F. Powell, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. B. Garon, T. Kurata, J. E. Gray, P. O. Schwarzenberger, E. Jensen, and D. Rodriguez Abreu
A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203), Ramaswamy Govindan, Mark M. Awad, Shirish M. Gadgeel, Jonathan A. Pachter, Gloria Patrick, and Louis J. Denis
DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes, Laura Graham, Edward Green, Joseph J. Park, Olesia Kellezi, Clara Hwang, Pedro C. Barata, Mehmet A. Bilen, Deepak Kilari, Melissa Clingerman, Abhishek Tripathi, Matthew Labriola, Shoshana Rothstein, Rohan Garje, Vadim S. Koshkin, Vaibhav G. Patel, Tanya B. Dorff, Andrew J. Armstrong, Rana R. McKay, Ajjai S. Alva, and Michael T. Schweizer
The role of African Duffy-null allele related inflammation on the tumor microenvironment, Yanira Guerra, Rachel Martini, Jessica Bensenhaver, Yalei Chen, Joseph K. Oppong, Ishmael Kyei, Frances S. Aitpillah, Michael O. Adinku, Joseph K. Oppong, Ernest K. Adjei, Aisha Jibril, Baffour Awuah, Mahteme Bekele, Engida Abebe, Kwasi Ankomah, Ernest B. Osei-Bonsu, Kofi K. Gyan, Clayton Yates, Kim Blenman, Olivier Elemento, Lisa Newman, and Melissa B. Davis
A retrospective study of the association of pre-autologous stem cell transplantation disease status with outcomes in patients with multiple myeloma: A single-center study, Radhika Gutta, Nino Balanchivadze, Kashmira Wani, Aroob Sweidan, Kylie Springer, and Philip Kuriakose
A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19, S. Halabi, B. Luo, H. Dzimitrowicz, Clara Hwang, T. M. Wise-Draper, C. Labaki, R. R. McKay, E. Ruiz, C. Rangel-Escareño, D. Farmakiotis, E. A. Griffiths, C. T. Jani, M. Accordino, C. Friese, E. Wulff-Burchfield, M. Puc, P. Yu, U. Topaloglu, S. Mishra, and J. Warner
790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel), Omid Hamid, Amy Weise, T. M. Kim, M. Mckean, N. Lakhani, J. Crown, J. Kaczmar, K. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo
Phase 1 study of fianlimab (FIAN), a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, plus cemiplimab (CEMI) in advanced melanoma (mel), O. Hamid, Amy Weise, Tae Min Kim, Meredith McKean, Nehal J. Lakhani, John Kaczmar, Kyriakos P. Papadopoulos, Shuquan Chen, Jayakumar Mani, Vladimir Jankovic, Glenn Kroog, Tasha Sims, Israel Lowy, and Giuseppe Gullo
790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel), O. Hamid, Amy Weise, T. M. Kim, M. A. Mckean, N. J. Lakhani, J. Kaczmar, K. P. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo
400P Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel), O. Hamid, Amy Weise, T. M. Kim, M. Mckean, N. Lakhani, J. Crown, J. Kaczmar, K. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo
Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, plus cemiplimab in advanced melanoma, O. Hamid, Amy Weise, T. M. Kim, M. McKean, N. J. Lakhani, J. Kaczmar, K. P. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo
Dose escalation of a phase 1b/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (pts) with metastatic solid tumors, Melissa L. Johnson, Raghad Abdul-Karim, David Sommerhalder, Navid Hafez, Shining Wang, Cheryl Li, Yuyin Liu, Lili Yang, Sabrina Collins, Xavier Parot, and James F. Strauss
NovelCombination to Enhance the Antitumor Activity ofKRASG12C Targeted Drugs, H. Y. Khan, S. F. Bannoura, A. Aboukameel, Y. Li, M. Al-Hallak, A. Al Sbihi, S. Kim, R. Beydoun, R. M. Mohammad, Y. Landesman, E. Baloglu, W. Senapedis, A. Sukari, M. Nagasaka, Philip A. Philip, B. El-Rayes, A. Shields, and A. S. Azmi
